ES2616295T3 - Agente para aplicar a mucosa y procedimiento para la producción del mismo - Google Patents

Agente para aplicar a mucosa y procedimiento para la producción del mismo Download PDF

Info

Publication number
ES2616295T3
ES2616295T3 ES06811990.8T ES06811990T ES2616295T3 ES 2616295 T3 ES2616295 T3 ES 2616295T3 ES 06811990 T ES06811990 T ES 06811990T ES 2616295 T3 ES2616295 T3 ES 2616295T3
Authority
ES
Spain
Prior art keywords
group
administration
chain
introduction
mucosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06811990.8T
Other languages
English (en)
Spanish (es)
Inventor
Kenji Miyamoto
Katsuya Takahashi
Yuuji Shimojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Application granted granted Critical
Publication of ES2616295T3 publication Critical patent/ES2616295T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES06811990.8T 2005-10-12 2006-10-12 Agente para aplicar a mucosa y procedimiento para la producción del mismo Active ES2616295T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005297170 2005-10-12
JP2005297170 2005-10-12
JP2006160478 2006-06-09
JP2006160478 2006-06-09
PCT/JP2006/320801 WO2007043702A1 (en) 2005-10-12 2006-10-12 Agent for applying to mucosa and method for production thereof

Publications (1)

Publication Number Publication Date
ES2616295T3 true ES2616295T3 (es) 2017-06-12

Family

ID=37942916

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06811990.8T Active ES2616295T3 (es) 2005-10-12 2006-10-12 Agente para aplicar a mucosa y procedimiento para la producción del mismo

Country Status (9)

Country Link
US (4) US20080306022A1 (cg-RX-API-DMAC10.html)
EP (1) EP1942912B1 (cg-RX-API-DMAC10.html)
JP (3) JP4387445B2 (cg-RX-API-DMAC10.html)
KR (4) KR101411067B1 (cg-RX-API-DMAC10.html)
CN (3) CN103120702B (cg-RX-API-DMAC10.html)
AU (1) AU2006300207C1 (cg-RX-API-DMAC10.html)
CA (1) CA2625532C (cg-RX-API-DMAC10.html)
ES (1) ES2616295T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007043702A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20080306022A1 (en) * 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
KR101460815B1 (ko) 2006-12-06 2014-11-12 세이가가쿠 고교 가부시키가이샤 관절염 질환 치료의 지속성 효과를 갖는 제약 제제
JP2009046454A (ja) * 2007-08-22 2009-03-05 Shiseido Co Ltd 口腔内用組成物
ITMI20072237A1 (it) * 2007-11-27 2009-05-28 Sigea Srl Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
JP5542687B2 (ja) * 2008-11-05 2014-07-09 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
CA2830933A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
US9067299B2 (en) 2012-04-25 2015-06-30 Applied Materials, Inc. Printed chemical mechanical polishing pad
CA2972212C (en) 2014-12-26 2024-10-29 Seikagaku Corporation AGENT AND IMPROVEMENT OF SUBJECTIVE OCULAR SYMPTOMS AND ASSOCIATED METHOD
CN104940221A (zh) * 2015-05-13 2015-09-30 北京大清生物技术有限公司 一种用于膀胱和尿道上皮损伤修复的组合物
US11253540B2 (en) 2015-05-29 2022-02-22 Seikagaku Corporation Composition including glycosaminoglycan derivative and chemokine receptor activity regulator
JP6757731B2 (ja) * 2015-08-20 2020-09-23 生化学工業株式会社 眼用デバイス適用剤
ES2979141T3 (es) * 2016-05-26 2024-09-24 Ophtecs Corp Preparación líquida para lentes de contacto que comprende derivado de ácido hialurónico hidrolizado y bactericida catiónico
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
ES2909998T3 (es) * 2016-10-14 2022-05-11 I Com Medical Gmbh Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック, インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
RU2652581C1 (ru) * 2017-07-03 2018-04-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения роговично-конъюнктивального ксероза
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
JP7660066B2 (ja) 2019-10-03 2025-04-10 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
US5733892A (en) * 1990-07-24 1998-03-31 Seikagaku Corporation Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
JP2855307B2 (ja) * 1992-02-05 1999-02-10 生化学工業株式会社 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法
DE4203529A1 (de) * 1992-02-07 1993-08-12 Wolff Walsrode Ag Wasserloesliche sulfoalkylhydroxyalkylderivate der cellulose und deren verwendung in gips- und zementhaltigen massen
ATE187821T1 (de) * 1994-03-14 2000-01-15 Seikagaku Kogyo Co Ltd Material zum tragen auf dem augapfel
US6025444A (en) * 1994-11-17 2000-02-15 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Cinnamic acid derivative
CA2162957C (en) * 1994-11-17 2011-08-02 Michinori Waki Cinnamic acid derivative
JP3308742B2 (ja) 1994-11-17 2002-07-29 生化学工業株式会社 光架橋性ヒアルロン酸誘導体とその架橋体およびそれらの製造方法
JP3955107B2 (ja) * 1995-05-01 2007-08-08 生化学工業株式会社 架橋多糖の製造法
US5789462A (en) * 1995-09-13 1998-08-04 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Photocured crosslinked-hyaluronic acid contact lens
JP4006039B2 (ja) * 1995-09-13 2007-11-14 生化学工業株式会社 光架橋ヒアルロン酸コンタクトレンズ
ES2179215T3 (es) * 1995-11-15 2003-01-16 Seikagaku Kogyo Co Ltd Gel de acido hialuronico con enlaces cruzados fotorreticulado y procedimiento para su preparacion.
EP0891775A4 (en) * 1996-12-27 2002-07-24 Seikagaku Kogyo Co Ltd MEDICINE FOR URBAN BLADDER DISORDERS
US6548487B2 (en) * 1996-12-27 2003-04-15 Seikagaku Corporation Agent for treatment of bladder troubles
JPH1171282A (ja) 1997-09-01 1999-03-16 Senju Pharmaceut Co Ltd 点眼用水性製剤
JP3014357B2 (ja) 1998-01-26 2000-02-28 生化学工業株式会社 角膜上皮層伸展促進剤
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
AU3327000A (en) * 1999-03-24 2000-10-09 Seikagaku Corporation Artificial saliva
PT1142566E (pt) 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
JP2001329002A (ja) * 2000-05-25 2001-11-27 Denki Kagaku Kogyo Kk 修飾ヒアルロン酸ゲルとその製造方法及びそれを含有する医用材料
JP2002037746A (ja) 2000-07-24 2002-02-06 Fuji Yakuhin:Kk キノロンカルボン酸系抗菌剤を含有する液剤
DE60117502T2 (de) * 2000-12-19 2006-08-24 Seikagaku Corp. Photohärtbare Derivate von Hyaluronsäure, Verfahren zu deren Herstellung, vernetztes und photogehärtetes Derivat der Hyaluronsäure und diese enthaltendes medizinisches Material
JP4172176B2 (ja) 2000-12-19 2008-10-29 生化学工業株式会社 光反応性ヒアルロン酸およびその製造方法ならびに光架橋ヒアルロン酸および医用材料
EP1353556A4 (en) * 2001-01-23 2009-09-09 Massachusetts Inst Technology SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS IN SOLID PHASE AND SOLUTION PHASE
JP4273208B2 (ja) * 2001-03-30 2009-06-03 チッソ株式会社 婦人科疾患治療剤
WO2006030965A1 (en) * 2004-09-15 2006-03-23 Seikagaku Corporation Photoreactive polysaccharide, photocrosslinked polysaccharide products, the method of making them and medical materials therefrom
US20080306022A1 (en) * 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
JP7023317B2 (ja) 2020-05-12 2022-02-21 沖電気工業株式会社 光波長フィルタ及び波長分離光回路

Also Published As

Publication number Publication date
CN103120701B (zh) 2014-11-05
KR101554834B1 (ko) 2015-09-21
KR20130109259A (ko) 2013-10-07
JP2009511423A (ja) 2009-03-19
CN101287473B (zh) 2013-01-02
CN103120701A (zh) 2013-05-29
CN103120702B (zh) 2014-11-05
KR101411067B1 (ko) 2014-06-27
WO2007043702A1 (en) 2007-04-19
AU2006300207C1 (en) 2012-05-24
US20080306022A1 (en) 2008-12-11
KR20080056012A (ko) 2008-06-19
JP5094799B2 (ja) 2012-12-12
US8969319B2 (en) 2015-03-03
KR20110120983A (ko) 2011-11-04
WO2007043702A9 (en) 2007-06-07
KR101428153B1 (ko) 2014-08-07
EP1942912A4 (en) 2010-10-06
US20150196574A1 (en) 2015-07-16
HK1184700A1 (en) 2014-01-30
CN101287473A (zh) 2008-10-15
EP1942912B1 (en) 2016-12-14
CN103120702A (zh) 2013-05-29
US20110207695A1 (en) 2011-08-25
US20180289730A1 (en) 2018-10-11
CA2625532A1 (en) 2007-04-19
JP4387445B2 (ja) 2009-12-16
CA2625532C (en) 2013-10-01
KR20140054368A (ko) 2014-05-08
HK1184701A1 (en) 2014-01-30
JP2012211171A (ja) 2012-11-01
AU2006300207B2 (en) 2011-12-01
EP1942912A1 (en) 2008-07-16
AU2006300207A1 (en) 2007-04-19
JP2009298798A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
US20180289730A1 (en) Agent for applying to mucosa and method for the production thereof
JP3439481B2 (ja) 光架橋ヒアルロン酸ゲルおよびその製造法
JP5147396B2 (ja) 薬剤導入光架橋ヒアルロン酸誘導体ゲル
ES2488942T3 (es) Sustancias diagnósticas para un análisis por formación de imágenes óptica sobre la base de formulaciones de nanopartículas
JP5291621B2 (ja) 関節疾患に対する持続的治療効果を有する薬剤
ES2568660T3 (es) Método de producción de derivados de ácido hialurónico
JP2009511423A5 (cg-RX-API-DMAC10.html)
ES2905606T3 (es) Conjugados de hialuronano con sustancias farmacéuticamente activas, métodos y composiciones
ES2708976T3 (es) Procedimiento para producir EMD de estabilidad aumentada
AU2012201314B2 (en) Agent for applying to mucosa and method for production thereof
HK1184700B (en) Use of glycosaminoglycan containing a binded hydrophobic group in the preparation of medicine for treating or preventing corneal epithelial layer disorders
HK1184701B (en) Use of glycosaminoglycan containing a binded hydrophobic group in the preparation of medicine for treating or preventing corneal epithelial layer disorders
ES2705602T3 (es) Composiciones de péptidos anfifílicos purificadas y usos de las mismas